Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ernexa Therapeutics Inc.ERNA · Entity 8278 | Director | August 31, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ernexa Therapeutics Inc.
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.57 · Expires 2036-08-31 | Direct | 5,943 |
Reported balance
After 2026-08-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-31 · Grant · Acquired 5,943 · Balance 5,943 F1: Subject to continued service, one-third of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 24 substantially equal monthly installments thereafter. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.57 · Expires 2036-08-31 | Direct | 5,083 |
Reported balance
After 2026-08-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-31 · Grant · Acquired 5,083 · Balance 5,083 F2: Represents options to purchase shares of the registrant's common stock in lieu of prorated director's cash compensation for 2026 pursuant to the Director's Compensation Plan effective August 15, 2026, granted under the Issuer's 2026 Omnibus Equity Incentive Plan. Subject to continued service, 100% of the stock options will vest on December 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continued service, one-third of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 24 substantially equal monthly installments thereafter.
F2: Represents options to purchase shares of the registrant's common stock in lieu of prorated director's cash compensation for 2026 pursuant to the Director's Compensation Plan effective August 15, 2026, granted under the Issuer's 2026 Omnibus Equity Incentive Plan. Subject to continued service, 100% of the stock options will vest on December 31, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 01:56 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | GrantStock Option (Right to buy) · Derivative | 5,083 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001493152-26-041135 · ownership.xml · derivative · entry 2 Cicala Peter · CIK 0002011534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,083 Underlying: Common Stock · 5,083 shares Expires 2036-08-31 F2 · derivative.exercise_date: Represents options to purchase shares of the registrant's common stock in lieu of prorated director's cash compensation for 2026 pursuant to the Director's Compensation Plan effective August 15, 2026, granted under the Issuer's 2026 Omnibus Equity Incentive Plan. Subject to continued service, 100% of the stock options will vest on December 31, 2026. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 01:56 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | GrantStock Option (Right to buy) · Derivative | 5,943 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001493152-26-041135 · ownership.xml · derivative · entry 1 Cicala Peter · CIK 0002011534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,943 Underlying: Common Stock · 5,943 shares Expires 2036-08-31 F1 · derivative.exercise_date: Subject to continued service, one-third of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 24 substantially equal monthly installments thereafter. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 00:00 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | GrantStock Option (Right to buy) · Derivative | 51,485 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001493152-25-005719 · ownership.xml · derivative · entry 1 Cicala Peter · CIK 0002011534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,485 Underlying: Common Stock · 51,485 shares Expires 2035-02-07 F1 · derivative.exercise_date: Subject to continued service, one-third of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 24 substantially equal monthly installments thereafter. Read SEC document |
| April 26, 2024 Filed Apr 29, 2024 20:31 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | GrantStock Option (Right to buy) · Derivative | 88,946 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001140361-24-023013 · form4.xml · derivative · entry 1 Cicala Peter · CIK 0002011534 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,946 Underlying: Common Stock · 88,946 shares Expires 2034-04-26 F1 · derivative.exercise_date: The stock option shall vest as to 100% of the number of shares subject to the stock option on the one-year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.